If you would like more information about the profile please click
. You will be directed to a new page where you will need
to provide some information about yourself/your business cooperation needs and submit
your expression of interest in the profile . A Network Partner will then contact
you to discuss your interest in greater detail.
A Dutch company offers a generally applicable technology to generate superior cell lines for biopharmaceutical protein production. Application of the technology allows cultured mammalian cells to produce more recombinant protein per cell. The company is looking for cooperation projects involving product and production technology development and for commercial agreement with biotech, pharma and diagnostic companies. A research cooperation agreement or a technical cooperation agreement is foreseen
Biopharmaceuticals are typically produced in cultured mammalian cells. The complex development and manufacturing method of these medicinal products results in their high pricing.
A Dutch biotech company has discovered and implemented genetic elements and developed highly cost-effective, production platforms for recombinant pharmaceutical proteins. Application of the technology increases production levels 2 to 3-fold compared to other systems commonly in use in the industry, resulting into improved efficiencies and lower production costs. Proof of value was demonstrated in different Chinese hamster ovary (CHO) cell types (e.g. adherent and suspension CHO-K1, CHO-DG44, CHO-GS) with different selection markers (e.g. blasticidin, puromycin, zeocin) for various proteins (e.g. monoclonal antibodies, biosimilars, difficult to express proteins).
Currently the Dutch SME focuses on two product classes: i. Biosimilars (generic biopharmaceuticals) and ii. difficult-to-express proteins (e.g. Fc-fusion proteins, bispecific proteins, membrane proteins, large multiple subunit proteins). For the latter, production inefficiencies currently prevent commercially viable levels and therefore inhibit their development. The technology is licensed to pharma companies.
The technology is patented, generally applicable (cell types, selection markers, expressed proteins), awarded and commercialized by licensing to pharmaceutical companies.
The SME is seeking collaboration with partners from companies and academia related to its expertise on producing proteins.
A research cooperation agreement is foreseen or a technical cooperation agreement, but also other types of collaboration can be discussed.
The cooperation types represents a broad range of R&D topics, such as the devolpment of mammalian cell-produced products and studying biopharmaceutical protein variants.
The SME's technology has the advantage that it allows more efficient production of biopharmaceutical proteins. For biosimilar this relates to facilitating protein production with high yield and at low costs.
For difficult to express proteins two important issues related to their production and limited availability can be solved: the inability to produce these proteins at commercially viable levels and the inability to easily prepare sufficient material to develop these kind of drug towards clinical studies.
Besides increasing its toolbox of genetic elements the Dutch SME also innovates by facilitating implementation of the technology and develop the technology towards a plug and play system.
Next generation development activities on-going
The technology is patented and generally applicable (e.g. cell types, selection markers, expressed proteins).
Patents have been applied and granted in the relevant regions: Europe, US, Australia, Canada and China.
The company is seeking collaboration with other companies (SME’s) and academia related to its expertise on producing proteins for development and research.
This represents a broad range of R&D topics. Partners from different application fields are invited, including partners developing mammalian cell-produced products, partners aiming to improve production by process engineering, partners interested in developing and studying biopharmaceutical protein variants, partners carrying out studies relating to protein production yield or its related metabolic processes, etc.
The Dutch SME is seeking both technical as well as research cooperation’s. It is interested in different programs, like Eurostars and FTI, as well as participation in consortia created to address topic-specific Horizon2020 and Horizon Europe calls.